Q1 Earnings Estimate for OmniAb Issued By Leerink Partnrs

OmniAb, Inc. (NASDAQ:OABI) – Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of OmniAb in a note issued to investors on Thursday, April 17th. Leerink Partnrs analyst P. Souda expects that the company will post earnings of ($0.16) per share for the quarter. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb’s Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.15) EPS.

Other equities research analysts have also issued reports about the stock. Benchmark lowered their target price on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Wednesday, March 19th. Finally, Royal Bank of Canada dropped their price objective on shares of OmniAb from $7.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, March 27th.

OmniAb Stock Up 1.1 %

Shares of OABI stock opened at $1.79 on Friday. The business has a 50-day simple moving average of $2.85 and a 200-day simple moving average of $3.46. OmniAb has a 52-week low of $1.70 and a 52-week high of $4.96. The stock has a market cap of $218.62 million, a PE ratio of -2.89 and a beta of 0.06.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $10.80 million for the quarter, compared to analyst estimates of $10.13 million. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. During the same quarter in the prior year, the business posted ($0.14) EPS.

Insider Activity

In other OmniAb news, CFO Kurt A. Gustafson sold 7,255 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $3.67, for a total transaction of $26,625.85. Following the sale, the chief financial officer now directly owns 206,211 shares in the company, valued at $756,794.37. This represents a 3.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew W. Foehr sold 41,811 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the transaction, the chief executive officer now directly owns 3,749,639 shares of the company’s stock, valued at approximately $12,148,830.36. The trade was a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 150,811 shares of company stock valued at $458,129 in the last 90 days. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On OmniAb

Several institutional investors have recently added to or reduced their stakes in OABI. Barclays PLC lifted its holdings in shares of OmniAb by 321.5% in the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares during the last quarter. FMR LLC boosted its holdings in shares of OmniAb by 10.6% in the third quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after acquiring an additional 13,324 shares during the period. State Street Corp grew its position in shares of OmniAb by 1.7% during the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after acquiring an additional 34,654 shares during the last quarter. Choreo LLC acquired a new position in shares of OmniAb in the 4th quarter valued at $41,000. Finally, Charles Schwab Investment Management Inc. raised its position in OmniAb by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 819,708 shares of the company’s stock valued at $2,902,000 after purchasing an additional 32,186 shares during the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.